BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34085994)

  • 1. Teprotumumab and Hearing Loss: Case Series and Proposal for Audiologic Monitoring.
    Belinsky I; Creighton FX; Mahoney N; Petris CK; Callahan AB; Campbell AA; Kazim M; Lee HBH; Yoon MK; Dagi Glass LR
    Ophthalmic Plast Reconstr Surg; 2022 Jan-Feb 01; 38(1):73-78. PubMed ID: 34085994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ototoxicity and Teprotumumab.
    Highland J; Gordon S; Reddy D; Patel N
    Ann Otol Rhinol Laryngol; 2022 Aug; 131(8):910-913. PubMed ID: 34448414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency and Patterns of Hearing Dysfunction in Patients Treated with Teprotumumab.
    Keen JA; Correa T; Pham C; Claussen AD; Hansen MR; Carter KD; Shriver EM
    Ophthalmology; 2024 Jan; 131(1):30-36. PubMed ID: 37567417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teprotumumab-associated chronic hearing loss screening and proposed treatments.
    Chow A; Silkiss RZ
    BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35418378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists.
    Chern A; Dagi Glass LR; Gudis DA
    Otolaryngol Head Neck Surg; 2021 Dec; 165(6):757-758. PubMed ID: 33781112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.
    Sears CM; Azad AD; Amarikwa L; Pham BH; Men CJ; Kaplan DN; Liu J; Hoffman AR; Swanson A; Alyono J; Lee JY; Dosiou C; Kossler AL
    Am J Ophthalmol; 2022 Aug; 240():1-13. PubMed ID: 35227694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Corticosteroids for Teprotumumab-Related Hearing Loss: A Case Report.
    Lu TJ; Amarikwa L; Winn BJ; Inserra M; Dosiou C; Kossler AL
    Case Rep Ophthalmol; 2023; 14(1):134-139. PubMed ID: 37034380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifle Blast Exacerbating Hearing Loss in a Patient Treated With Teprotumumab for Thyroid Eye Disease.
    Reed DS; Kostosky N; Davies BW; Epstein A; Durairaj VD
    Ophthalmic Plast Reconstr Surg; 2022 Mar-Apr 01; 38(2):e41-e43. PubMed ID: 34652314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensorineural Hearing Loss After Teprotumumab Therapy for Thyroid Eye Disease: A Case Report.
    Ding AS; Mahoney NR; Campbell AA; Creighton FX
    Otol Neurotol; 2022 Feb; 43(2):e148-e152. PubMed ID: 34789694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teprotumumab for the treatment of thyroid eye disease.
    Ju Y; Yang J
    Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of Teprotumumab-Induced Hearing Loss With Comparable Efficacy Using Half-Dose Therapy.
    Phansalkar R; Lu T; Alyono J; Lee J; Dosiou C; Kossler AL
    Ophthalmic Plast Reconstr Surg; 2023 Jul-Aug 01; 39(4):e101-e104. PubMed ID: 36877549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Adverse Effects Profile of Teprotumumab.
    Stan MN; Krieger CC
    J Clin Endocrinol Metab; 2023 Aug; 108(9):e654-e662. PubMed ID: 37071658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teprotumumab: A Review in Thyroid Eye Disease.
    Nie T; Lamb YN
    Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Audiology findings in patients with teprotumumab associated otologic symptoms.
    Yu CY; Correa T; Simmons BA; Hansen MR; Shriver EM
    Am J Ophthalmol Case Rep; 2021 Dec; 24():101202. PubMed ID: 34585021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease.
    Hoang TD; Nguyen NT; Chou E; Shakir MK
    BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 33972303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
    Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
    Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Side Effects and Adverse Events After Treatment With Teprotumumab for Thyroid Eye Disease: A Retrospective Observational Case Series.
    Mukit FA; Manley A; Patel AB; Hashemi M; Laplant JF; Fleming JC; Fowler BT
    Cureus; 2024 Apr; 16(4):e58585. PubMed ID: 38765324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.